Our previous work demonstrated that the FLT3 inhibitors midostaurin and gilteritinib can downregulate Mcl-1 and synergy with anti-F L T 3 mutation-positive AML activity with ABT-199 [27]. Here, MCL1 is linked to acute myeloid leukemia.